For Patients With a Positive Sentinel Node in Breast Cancer, Radiotherapy is Comparable to Dissection

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal The Lancet Oncology, dissection and radiotherapy of the axillary lymph node following a positive sentinel node are effective approaches for proving axillary control in patients with T1-2 primary breast cancer without palpable lymphadenopathy.

For the randomized, multicenter, open-label, phase 3 non-inferiority AMAROS study, researchers randomly assigned 4,806 patients to receive axillary lymph node dissection, the current standard of care, or axillary radiotherapy. Patients with positive sentinel lymph nodes were followed for a median of 6.1 years.

Of the 744 patients with a positive sentinel node in the axillary lymph node dissection group, four patients experienced axillary recurrence compared with seven of 681 patients with a positive sentinel node in the axillary radiotherapy group. Results showed a 5-year axillary recurrence rate of 0.43% (95% CI, 0.00 - 0.92) in the dissection group compared with 1.19% (95% CI, 0.31-2.08) in the radiotherapy group.

Axillary lymph node dissection was more often associated with lymphoedema in the ipsilateral arm versus axillary radiotherapy after 1, 3, and 5 years. The findings suggest that axillary radiotherapy provides equivalent regional control with fewer adverse effects versus axillary lymph node dissection.

Cryoablation Promising for Early Invasive Breast Cancer
Radiotherapy of the axillary lymph node following a positive sentinel node effective approach.
The authors aimed to assess whether axillary radiotherapy provides comparable regional control with fewer side–effects. Axillary lymph node dissection and axillary radiotherapy after a positive sentinel node provide excellent and comparable axillary control for patients with T1—2 primary breast cancer and no palpable lymphadenopathy. Axillary radiotherapy results in significantly less morbidity.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs